ThermoGenesis jumps following trial results


ThermoGenesis (KOOL) surges 32% after the company reported, along with its partner TotipotentRX, statistically significant results in five key areas in a Phase Ib trial of the latter's CLIRST stem-cell therapy for treating critical limb ischemia.

The study comprised 17 patients and achieved its primary safety and secondary efficacy endpoints at 12 months.

The areas that were assessed included survival rates that didn't require major amputations, a fall in resting and walking pain, improved walking distance and open wound healing.

Critical limb ischemia is a severe blockage in the arteries in the lower extremities. (PR)

Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs